已收盘 12-19 16:00:00 美东时间
-0.030
-4.41%
Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its
12-20 05:06
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalitiesNew delivery model for ReWalk will integrate in-patient
12-17 21:13
①周三美股盘中,多只机器人概念股走强,Nauticus Robotics和iRobot双双涨逾60%;②消息人士透露,美国政府考虑在明年发布一项关于机器人技术的行政命令,卢特尼克近期一直在与机器人行业CEO会面。
12-04 02:36
今日重点评级关注:Oppenheimer:维持Olema Pharmaceuticals"跑赢大市"评级,目标价从22美元升至45美元;Bernstein:维持Atlassian"跑赢大市"评级,目标价从290美元升至304美元
11-19 11:01
Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received
11-17 21:05
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Lifeward业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 总营收620万美元,同比增长1.1%(去年同期610万美元),环比增长8%(上季度570万美元) - 传统产品营收310万美元,同比增长24%(去年同期250万美元),主要由ReWalk产品贡献290万美元 - ATLAS G产品营收310万美元,同比下降13.9%(去年同期360万美元) **盈利能力:** - GAAP毛利润270万美元,毛利率43.7%,同比提升7.5个百分点(去年同期220万美元,毛利率36.2%) - Non-GAAP毛利
11-15 12:13
Lifeward (NASDAQ:LFWD) affirms FY2025 sales outlook from $24.000 million-$26.000 million to $24.000 million-$26.000 million vs $25.101 million estimate.
11-14 21:02
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 11.63 percent. This is a 57.78 percent increase over losses of $(0.45) per share from the same
11-14 21:01
Companies Reporting Before The Bell • Inhibrx Biosciences (NASDAQ:INBX) is expe...
11-14 19:11
Lifeward (NASDAQ:LFWD) is preparing to release its quarterly earnings on Friday...
11-14 00:02